Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry
European Journal of Neurology · 2023
DOI: 10.1111/ene.15740 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Neurology, 2023. Verfasst von Andreas A Argyriou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Headache Outpatient Clinic, Neurology Department, Agios Andreas State General Hospital of Patras, Patras, Greece. Hauptthemen laut MEDLINE: Quality of Life, Migraine Disorders. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Objective
To prospectively assess the efficacy and safety of fremanezumab for migraine prophylaxis in patients with failure of at least three previous preventive treatments. Changes in disability as quality‐of‐life outcomes after fremanezumab treatment were also examined.
Methods
Two hundred and four patients with either high‐frequency EM (HFEM) or chronic migraine (CM), who attained at least three consecutive monthly sessions with fremanezumab 225 mg and otherwise met the inclusion criteria, were included in the study. The crude response (at least 50% reduction in monthly headache days [MHD]) rates to fremanezumab were assessed. Scores in the following efficacy outcomes were then compared from baseline to the last efficacy evaluation follow‐up: (i) MHD, (ii) monthly days with moderate/severe peak headache intensity, and (iii) monthly days with intake of abortive medication. The disability was evaluated with the Migraine Disability Assessment; the quality of life (QOL) status was assessed with the Headache Impact‐6 Test, and the EQ‐5D questionnaire.
Results
In the majority of HFEM cases ( n = 81/97; 83.5%) and CM patients ( n = 67/107; 62.6%), fremanezumab proved effective in reducing the MHDs by at least 50% and was associated with clinically meaningful improvement in all other efficacy variables. The migraine‐related disability experienced by our patients decreased and their QOL increased. We recorded just 36 cases reporting mild adverse events, including pain, rash or pruritus ( n = 26), flu‐like symptoms ( n = 8), and hair loss ( n = 2).
Conclusion
With our prospective results, we provide further real‐world data to support the favorable benefit/risk profile of fremanezumab in the prophylaxis of both HFEM and CM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Headache Outpatient Clinic, Neurology Department, Agios Andreas State General Hospital of Patras, Patras, Greece.
- Department of Neurology, Euromedica General Clinic, Thessaloniki, Greece.
- Department of Neurology, School of Medicine, University of Thessaly, Larissa, Greece.
- Department of Neurology, Tzaneio General Hospital of Piraeus, Athens, Greece.
- Private Practice, Kalamata, Greece.
- Headache Clinic, Mediterraneo Hospital, Glyfada, Greece.
Zitieren
APA
Argyriou, A. A., Dermitzakis, E. V., Xiromerisiou, G., Rallis, D., Soldatos, P., Litsardopoulos, P., & Vikelis, M. (2023). Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry. European Journal of Neurology. https://doi.org/10.1111/ene.15740
Vancouver
Argyriou AA, Dermitzakis EV, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P, et al. Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry. European Journal of Neurology. 2023. doi:10.1111/ene.15740
BibTeX
@article{Argyriou2023,
author = {Argyriou, Andreas A and Dermitzakis, Emmanouil V and Xiromerisiou, Georgia and Rallis, Dimitrios and Soldatos, Panagiotis and Litsardopoulos, Pantelis and Vikelis, Michail},
title = {Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry},
journal = {European Journal of Neurology},
year = {2023},
doi = {10.1111/ene.15740}
}
EUVIMED